HRSA-CDC Partners Chart Steady Course

Dr. George Sigounas met with the CDC/HRSA Advisory Committee earlier this month to outline agency successes in the past year -- including awarding over $396 million to combat the opioid crisis. The Administrator reaffirmed HRSA’s commitment to “continue to provide HIV care and treatment services to the most vulnerable people living with HIV” through the Ryan White HIV/AIDS program.
Dr. George Sigounas met with the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment earlier this month to outline agency successes in the past year -- including awarding over $396 million to combat the opioid crisis. The Administrator reaffirmed HRSA’s commitment to “continue to provide HIV care and treatment services to the most vulnerable people living with HIV” through the Ryan White HIV/AIDS program.

 

Dr. Laura Cheever, Associate Administrator of HRSA's HIV/AIDS Bureau, reported several large studies have demonstrated that people living with HIV who remain in care and on viral suppression medication do not sexually transmit the HIV virus.  By adhering to their HIV medications as prescribed and maintaining an undetectable viral load, they have "effectively no risk" of infecting an HIV-negative partner.
Dr. Laura Cheever, Associate Administrator of HRSA's HIV/AIDS Bureau, reported several large studies have demonstrated that people living with HIV who remain in care and on viral suppression medication do not sexually transmit the HIV virus.  By adhering to their HIV medications as prescribed and maintaining an undetectable viral load, they have "effectively no risk" of infecting an HIV-negative partner.

 

HAB continues to work innovatively across the agency and HHS to deliver that information and related messages - to clients served through the Ryan White HIV-AIDS Program - about viral suppression, the connection between the opioid epidemic and HIV, and screening and treating sexually transmitted infections.

Toward those ends, Cheever added, telehealth technology is now explicitly allowed and eligible for funding as a means of providing HIV services.

 

Photo of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment

 

In another announcement, Kaye Hayes -- Deputy Director, HHS Office of HIV/AIDS and Infectious Disease Policy -- told the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment that she expects both the National HIV/AIDS Strategy and the National Viral Hepatitis Action Plan to be updated by 2020.

"We really need to establish ambitious goals and targets and be aggressive in that," Hayes said. "We really need to identify the most efficient and effective strategies and make the bold decisions -- that if we need to 'course-correct,' we have the courage to do so."

Date Last Reviewed:  November 2018